HOME >> BIOLOGY >> NEWS
Cytokine resistance contributes to pathology of type 2 diabetes

In a study appearing this month in the Journal of Immunology, researchers at the University of Illinois describe how an impaired anti-inflammatory response plays a role in the pathology of type 2 diabetes.

Type 2 diabetes is classified as a metabolic disorder, but a growing number of researchers are beginning to think of it also as a disease of the innate immune system. Inflammation, a key component of the early immune response, is chronically elevated in people with type 2 diabetes. While the pro-inflammatory pathways of type 2 diabetes have received much attention, the anti-inflammatory side of the equation is less well known.

The new study focused on a number of cytokines, protein signals that bind to specific receptors on cells and set off a cascade of biochemical reactions within the cell. Interleukins, interferons, tumor necrosis factors and some growth factors are among the cytokines that direct many aspects of the immune response. Cytokines are secreted by many types of cells, including the immune cells known as macrophages.

In earlier studies, the researchers had shown that macrophages in diabetic and obese (diabese) mice secrete more pro-inflammatory and less anti-inflammatory cytokines than those of nondiabese mice. The team, led by pathology professor and department head Gregory Freund, also had demonstrated that human monocytes cultured under type 2 diabetic conditions had impaired interleukin-4 signaling. Interleukin 4 (IL-4) is an important player in the immune response in that it steers macrophages toward the production of other anti-inflammatory cytokines. It also inhibits secretion of the pro-inflammatory cytokines.

When IL-4 binds to its receptor on a target cell, it sets off one of two cascades of intracellular events.

The first of these signal transduction pathways, the Jak-STAT pathway, is well studied and well understood. The second, called the insulin receptor substrate 2 / phosphatidylinos
'"/>

Contact: Diana Yates
diya@uiuc.edu
217-333-5802
University of Illinois at Urbana-Champaign
14-Jun-2007


Page: 1 2

Related biology news :

1. Cytokinetics presents data on CK-1827452
2. Support for chromosomal theory of cancer found in cancers development of drug resistance
3. 454 sequencing identifies HIV drug resistance at early stage
4. Ultra deep sequencing identifies HIV drug resistance at early stage
5. Largest synthetic gene ever built offers insights into anti-malarial drug resistance
6. WHO data confirms low level of resistance to Tamiflu
7. Unstable leukemia stem cells may predispose patients to drug resistance
8. Gene profiling predicts resistance to breast cancer drug Herceptin
9. IDIBAPS participates in European Network on antibiotic resistances and hospital infections
10. What recognizes what in plant disease resistance?
11. Antiretroviral resistance testing in HIV infected patients improves health and saves costs

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/9/2019)... ... May 09, 2019 , ... Akadeum Life Sciences today announced ... its microbubble technology. Unlike magnetic-based products, microbubbles use buoyancy to gently separate cells ... who participated in an early access program has been very encouraging and has ...
(Date:5/8/2019)... ... May 08, 2019 , ... ... diameter of 200 microns and a lead-in fiber of 100 microns. With dimensions ... standard and positioning itself as the world leader in the development of fiber ...
(Date:5/2/2019)... (PRWEB) , ... May 01, 2019 , ... ... that give families insight into their future children, announces a new publication titled, ... in the journal of Pregnancy and Child Health. Previous studies had only shown ...
Breaking Biology News(10 mins):
(Date:4/25/2019)... ... April 24, 2019 , ... Inference Solutions ... service organizations, today announced global availability of Inference Studio’s latest version, which makes ... sizes to harness the power of Google’s Contact Center AI (CCAI). ...
(Date:4/15/2019)... ... April 15, 2019 , ... Sirrus, Inc., ... $2 million bench plant expansion to increase production of methylene malonate monomers and ... and construction of Sirrus’ full-scale production facility, which is scheduled to break ground ...
(Date:4/9/2019)... ... April 09, 2019 , ... USDM ... capacity of life sciences organizations to accelerate innovation and maximize productivity, announces that ... the past 12 months. , USDM’s Cloud Assurance is a managed ...
(Date:4/8/2019)... SAN FRANCISCO (PRWEB) , ... April 08, 2019 , ... ... to accredited investors a $15 million preferred equity investment in the privately held pharmaceutical ... dysfunction. Its leading drug, Lorexys, is targeted at female hypoactive sexual dysfunction disorder and ...
Breaking Biology Technology:
Cached News: